Investigational drug · Phase 2
TQB6411
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Lung Cancer, Esophageal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TQB6411"
First trial start
2026
Feb 12, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB6411", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Lung Cancer
- Esophageal Cancer
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB6411" as an intervention, largest first.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07367529 · 465 participants (planned) · Start Feb 26, 2026 · Primary completion Dec 2028
Drug: TQB6411 for Injection · For: Advanced Lung Cancer
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 38 sites in all
- A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant TumorsRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07043751 · 216 participants (planned) · Start Jul 15, 2025 · Primary completion Dec 2027
Drug: TQB6411 injection · For: Advanced Malignant Tumors
Sites: Beijing, China; Dongguan, China; Guangdong, China · 19 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07367516 · 105 participants (planned) · Start Feb 12, 2026 · Primary completion Feb 2027
Drug: TQB6411 Injection · For: Esophageal Cancer
Sites: Hefei, China; Beijing, China; Fuzhou, China · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Lung Cancer
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- AL2846Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Thyroid Cancer, Differentiated Thyroid Cancer, Advanced Lung Cancer
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
- MHB036CPhase 23 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.